PAVmed (PAVM) Operating Margin (2021 - 2025)
PAVmed's (PAVM) quarterly Operating Margin came in at 8398.77% in Q4 2025, up 4347123.0% year-on-year from N/an in Q4 2024, and up 91.33% quarter-over-quarter from 96880.0% in Q3 2025.
PAVmed (PAVM) Operating Margin (2021 - 2025) Analysis & Trends
PAVmed's Operating Margin history runs 5 years deep, the most recent figure standing at 8398.77% for Q4 2025.
- On a quarterly basis, Operating Margin rose 4347123.0% year-over-year to 8398.77% in Q4 2025; TTM through Dec 2025 was 21808.0%, a 2019087.0% decrease from a year earlier, with the FY2025 full-year figure at 21806.0%, down 2032062.0% from the prior year.
- Operating Margin grew to 8398.77% in Q4 2025 per PAVM's latest filing, from 96880.0% in the prior quarter.
- Across five years, Operating Margin topped out at 1389.7% in Q1 2024 and bottomed at 96880.0% in Q3 2025.
- The 5-year median for Operating Margin is 9164.44% (2023), against an average of 25069.85%.
- Biggest YoY gain for Operating Margin was 4347123 bps in 2025; the steepest drop was 7718558 bps in 2025.
- Year by year, Operating Margin stood at 6559.67% in 2021, then sank by 235 bps to 21965.18% in 2022, then surged by 93 bps to 1561.77% in 2023, then plunged by 3221 bps to 51870.0% in 2024, then jumped by 84 bps to 8398.77% in 2025.
- Per Business Quant, the three latest PAVM Operating Margin figures stand at 8398.77% (Q4 2025), 96880.0% (Q3 2025), and 78583.33% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | PAVmed | 9.85 Mn | -3.35 Mn | -4,000.00 | -8,398.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8,398.77% |
| Sep 30, 2025 | -96,880.00% |
| Jun 30, 2025 | -78,583.33% |
| Mar 31, 2025 | -68,075.00% |
| Dec 31, 2024 | -51,870.00% |
| Jun 30, 2024 | -1,397.75% |
| Mar 31, 2024 | -1,389.70% |
| Dec 31, 2023 | -1,561.77% |
| Sep 30, 2023 | -1,963.08% |
| Jun 30, 2023 | -9,930.12% |
| Mar 31, 2023 | -4,574.22% |
| Dec 31, 2022 | -21,965.18% |
| Sep 30, 2022 | -30,746.05% |
| Mar 31, 2022 | -10,388.89% |
| Dec 31, 2021 | -6,559.67% |
| Sep 30, 2021 | -6,834.00% |